Categories: News
Published: 17 July 2025
Gene Solutions Presents 11 Posters at ESMO TAT Asia 2025: Advancing the Future of Precision Oncology
Gene Solutions is proud to participate in ESMO TAT Asia 2025, held in Hong Kong from July 18–20. At this prestigious event, we will host an interactive booth and present 11 cutting-edge posters, covering novel approaches in neoantigen discovery, AI-powered immunotherapy design, genomic & transcriptomic profiling, circulating tumor DNA (ctDNA) monitoring, and organoid-based drug development.
| No. | Title & Author | Description |
| Neoantigen & Vaccine Development | ||
|---|---|---|
| 54P | Comprehensive Tumor Profiling and Biomodeling-Guided Discovery of Shared Neoantigens for Off-the-Shelf Vaccines in Colorectal Cancers in Asia*
Author: Tran Thi Phuong Diem |
We developed and validated a shared neoantigen panel tailored for Asian colorectal cancer patients, using large-scale genomic datasets and functional immunogenicity assays. The panel covers common HLA-I alleles and includes neoantigens from non-druggable targets like TP53, which elicited potent cytotoxic T cell responses. This work supports the rapid, off-the-shelf development of vaccines guided by our comprehensive tumor profiling platform, IMMDIRECT. |
| 53P | Exploiting Fusion-Derived Neoantigens for Adjuvant Therapy in Colorectal Cancer
Author: Nguyen Bui Que Tran |
Personalized cancer immunotherapy targeting neoantigen-specific T cells is crucial for designing effective treatments. However, current approaches to identifying reactive T cell receptors (TCRs) primarily rely on costly and time-consuming single-cell TCR sequencing. In this study, we evaluated whether integrating proprietary in silico tools—designed to model the complex binding interactions among HLA molecules, neoantigens, and TCRs at the immunological synapse—could enable the selection and prioritization of reactive TCR clones from bulk TCR sequencing data, thereby supporting personalized TCR-T therapy. |
| 61P | Improving Neoantigen Prediction Using Long Immunogenic Peptides
Author: Ho Thi Kim Cuong |
Long immunogenic peptides are crucial for effective cancer immunotherapies, serving as superior sources of neoantigens that overcome the suboptimal T-cell activation often associated with short peptides. To address this, LPstack, an innovative ensemble stacking model, has been developed as one of the few immunogenicity prediction tools specifically designed for long peptides. This advanced model significantly outperforms existing approaches like NetMHCpan and Nmer, offering higher sensitivity and holding greater potential for developing more effective cancer treatments. |
| AI-Powered Immunotherapy and TCR-T Therapy | ||
| 90P | Integrating AI-based prediction tools with bulk TCR sequencing enables rapid and cost-effective identification of TCR clones for personalized TCR-T therapy*
Author: Pham Thi Mong Quynh |
Personalized cancer immunotherapy targeting neoantigen-specific T cells is crucial for designing effective treatments. However, current approaches to identifying reactive T cell receptors (TCRs) primarily rely on costly and time-consuming single-cell TCR sequencing. In this study, we evaluated whether integrating proprietary in silico tools—designed to model the complex binding interactions among HLA molecules, neoantigens, and TCRs at the immunological synapse—could enable the selection and prioritization of reactive TCR clones from bulk TCR sequencing data, thereby supporting personalized TCR-T therapy. |
| 55P | epiTCR-CLFP: AI-Enabled Neoantigen & TCR Matching to Empower Personalized Cancer Vaccines
Author: Pham Nguyen My Diem |
Identifying TCRs that recognize specific peptides remains a major challenge due to data sparsity, class imbalance, and poor generalization of existing models. We introduce epiTCR-CLFP, a contrastive learning model predicting TCR–peptide binding with strong generalization to unseen data and robust performance on class imbalance. Using structure-aware molecular fingerprints, it accurately identifies true binders—including tetramer-positive and neoantigen-specific TCRs. This AI-powered approach advances personalized immunotherapy by enabling precise neoantigen and TCR selection |
| 54P | Integrating Patient TCR Repertoires for Precision Neoantigen Selection and Prioritization in Personalized Cancer Vaccines
Author: Nguyen Ngoc Bao Tran |
Neoantigen vaccines are an emerging personalized immunotherapy, yet effective neoantigen selection remains challenging. Current methods mainly rely on HLA-peptide binding affinity but overlook the critical role of the TCR in recognizing the peptide-HLA complex. Hence, we developed NeoPick, a neoantigen selection workflow that ranks neoantigens in colorectal patients based on the differential binding between mutant vs wild-type peptides to both HLA and TCR. This approach provides effective and accurate neoantigen prioritization, facilitating the development of personalized cancer vaccines |
| ctDNA Monitoring & Multi-Omics Profiling | ||
| 95P | Integrating plasma ctDNA detection and tumor comprehensive genomic and transcriptomic profiling to maximize the clinical implications of precision oncology*
Author: Thien-Phuc Hoang Nguyen |
NK cell therapy has emerged as a promising approach for cancer immunotherapy due to its versatility and favorable safety profile. However, precise target recognition and anti-tumor activity of NK cells still need improvement for clinical use. Here we examined the balance of activating and inhibitory ligands present in different solid tumors, which might predict the tumor responsiveness to allogenic NK cell therapy. |
| 96P | Direct comparison of tumor-informed and tumor-agnostic ctDNA assays in non-small cell lung cancer*
Author: Nguyen Hoang Van Anh |
Circulating tumor DNA (ctDNA) is a promising prognostic biomarker in early-stage non-small cell lung cancer (NSCLC). The typical tumor-informed method of ctDNA testing requires tissue specimens of high quality, which is a challenge in developing countries. Tumor-naïve approach is an alternative, but performance of the two methods has not been directly compared using same samples and platform. |
| Next-Generation Immunotherapy Targets | ||
| 25P | Cancer-specific NK ligand signatures could predict tumor responsiveness to allogenic NK cell therapy*
Author: Tran Huynh Bao Nam |
NK cell therapy has emerged as a promising approach for cancer immunotherapy due to its versatility and favorable safety profile. However, precise target recognition and anti-tumor activity of NK cells still need improvement for clinical use. Here we examined the balance of activating and inhibitory ligands present in different solid tumors, which might predict the tumor responsiveness to allogenic NK cell therapy. |
| 13P | A novel KRASG12V-targeted bispecific T-cell engager promotes immunity against colorectal solid tumor
Author: Thu My Nguyen Thi |
KRAS mutations are detected at highly rates in various tumor types, making it one of the most commonly mutated oncogenes. Limited relevant binding pockets have rendered these mutants undruggable for many decades, especially for KRASG12V mutant. Recent advances in T cell receptors (TCRs) profiling have shed light to overcome this limitation by recognizing neoantigens presented by human lymphocyte antigen (HLA) and inducing T cell-mediated killing responses. Using previously identified KRASG12V-targeting TCR, we engineered the bispecific T-cell engager receptors (TCERs) with high efficiency and specificity for the KRASG12V/HLA-A*11:01 tetramer. |
| Organoid-Based Precision Oncology | ||
| 106P | Building an Asian Patient-Derived Organoid Biobank for Precision Oncology (Vietnamese Organoid Biobank: A Platform for Precision Medicine and Immunotherapy)
Author: Dang Hieu Thong |
Patient-derived tumor organoids are generated from dissociated single cells of resected tumor tissues, preserving the heterogeneity of the original patient tumor. As such, they offer a more physiologically relevant cancer model compared to traditional 2D cultures. We present our integrated, all-in-one platform built upon a comprehensive patient-derived cancer organoid biobank to support the development of cancer therapies. This platform enables a wide range of applications, including rapid genomic and transcriptomic profiling, high-throughput drug screening, and the development of immunotherapies. |
*Merit Travel Grants
These presentations underscore our commitment to transforming advanced research into accessible, practical, and region-specific oncology solutions.
About Gene Solutions
Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology – from early detection to real-time treatment monitoring.
With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.
